Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New dissolvable implant shows promise for smoothing wrinkles

NCT ID NCT07617350

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a medical device called ULTRACOL, a dissolvable implant placed under the skin, to see if it can safely improve wrinkles and other skin contour problems. 23 adults with facial wrinkles or skin aging took part. The main goal was to measure changes in wrinkle severity using a standard rating scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Jul 2024

Finished

Apr 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The subject has indications for use according to the manufacturer instructions for the device. * The subject is at least 18 years old at the time of signing the informed consent. * The subject expresses willingness and ability to follow the requirements of the study protocol. * The subject has no contraindications described in the device instructions for use. Exclusion Criteria: * The subject has at least one contraindication described in the device instructions for use, based on initial examination, laboratory tests and medical history. * Women of reproductive age: pregnancy, planning pregnancy during the study period, or breastfeeding. * Use of another product for the same indication during the clinical study. * Participation in another clinical study. * Pre-existing health problems that may compromise compliance with the study protocol. * Patients prone to excessive scarring. * Patients undergoing chemotherapy. * Patients previously treated with intradermal fillers in the planned injection zone with persistent effect.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Facial lipoatrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Estelab CLinic

    Moscow, Russia, 119034, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.